Skip to main content

News

You are here

HHS Advances Development of Profectus BioSciences Inc. Ebola Vaccine: Company is UMB spinout

Friday, October 17, 2014

Studies will prepare vaccine candidate for clinical trials

The development of a vaccine to prevent Ebola virus disease will be accelerated with support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). 

Under a one-year contract with Profectus BioSciences Inc., headquartered in Baltimore, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will provide approximately $5.8 million in funding, in addition to subject matter expertise and technical assistance, to further develop an experimental Ebola vaccine. The company will manufacture vaccine for use in animal safety studies and future clinical trials and conduct animal studies to test safety. The contract can be extended to a total of 13 months and $8.6 million.

Read more >> http://www.hhs.gov/news/press/2014pres/10/20141016a.html